This page uses content from Wikipedia and is licensed under CC BY-SA.

Rimegepant

Rimegepant
Rimegepant.svg
Clinical data
Other namesBHV-3000, BMS-927711
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H28F2N6O3
Molar mass534.568 g·mol−1
3D model (JSmol)

Rimegepant (BHV-3000; formerly BMS-927711) is an investigational drug candidate for the treatment of migraine. Originally discovered at Bristol-Myers Squibb,[1] it is currently under development by Biohaven Pharmaceuticals.[2]

Mechanism of action

Rimegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist.[3]

References

  1. ^ "Drug Profile: Rimegepant". Adis Insight.
  2. ^ "Rimegepant (BHV-3000) – for acute treatment of Migraine". Biohaven Pharmaceuticals.
  3. ^ Diener, Hans-Christoph; Charles, Andrew; Goadsby, Peter J; Holle, Dagny (2015). "New therapeutic approaches for the prevention and treatment of migraine". The Lancet Neurology. 14 (10): 1010. doi:10.1016/S1474-4422(15)00198-2. PMID 26376968.